CD133 as a Target for Cancer Treatment
Author Information
Author(s): Smith L M, Nesterova A, Ryan M C, Duniho S, Jonas M, Anderson M, Zabinski R F, Sutherland M K, Gerber H-P, Van Orden K L, Moore P A, Ruben S M, Carter P J
Primary Institution: Seattle Genetics Inc.
Hypothesis
Can CD133 be effectively targeted in hepatocellular and gastric cancers using antibody-drug conjugates?
Conclusion
The study found that targeting CD133 with antibody-drug conjugates can significantly inhibit tumor growth in certain cancer cell lines.
Supporting Evidence
- CD133 was found to be highly expressed in over 50% of pancreatic, gastric, and intrahepatic cholangiocarcinomas.
- Anti-CD133-drug conjugate treatment resulted in significant delay of Hep3B tumor growth in SCID mice.
- Quantitative flow cytometric analysis showed that cancer cell lines expressed CD133 at levels higher than normal cells.
Takeaway
Scientists are trying to use a special medicine that targets a protein called CD133 to help fight certain types of cancer.
Methodology
The study involved in vitro and in vivo experiments using cancer cell lines and mouse models to evaluate the effectiveness of an anti-CD133 antibody-drug conjugate.
Limitations
The study's findings may not be generalizable to all cancer types due to the specific focus on hepatocellular and gastric cancers.
Statistical Information
P-Value
0.0001
Statistical Significance
p=0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website